首页> 外文期刊>Bioconjugate Chemistry >A Versatile Bifunctional Chelate for Radiolabeling Humanized Anti-CEA Antibody with In-111 and Cu-64 at Either Thiol or Amino Groups: PET Imaging Of CEA-Positive Tumors with Whole Antibodies
【24h】

A Versatile Bifunctional Chelate for Radiolabeling Humanized Anti-CEA Antibody with In-111 and Cu-64 at Either Thiol or Amino Groups: PET Imaging Of CEA-Positive Tumors with Whole Antibodies

机译:多功能双功能螯合物,用于在硫醇或氨基上以In-111和Cu-64放射性标记人源化抗CEA抗体:带有完整抗体的PET阳性CEA肿瘤的PET成像

获取原文
获取原文并翻译 | 示例
           

摘要

Radiolabeled anti-carcinoembryonic antigen (CEA) antibodies have the potential to give excellent images of a wide variety of human tumors, including tumors of the colon, breast, lung, and medullar thyroid. In order to realize the goals of routine and repetitive clinical imaging with anti-CEA antibodies, it is necessary that the antibodies have a high affinity for CEA, low cross reactivity and uptake in normal tissues, and low immunogenicity. The humanized anti-CEA antibody hT84.66-M5A (M5A) fulfills these criteria with an affinity constant of > 10~(10) M~(-1), no reactivity with CEA cross-reacting antigens found in normal tissues, and >90% human protein sequence. A further requirement for routine clinical use of radiolabeled antibodies is a versatile method of radiolabeling that allows the use of multiple radionuclides that differ in their radioemissions and half-lives. We describe a versatile bifunctional chelator, D03A-VS (1,4,7-tris(carboxymethyl)-10-(vinylsulfone)-1,4,7,10-tetraazacyclodode-cane) that binds a range of radiometals including ~(111)In for gamma-ray imaging and ~(64)Cu for positron emission tomography (PET), and which can be conjugated with negligible loss of immunoreactivity either to sulfhydryls (SH) in the hinge region of lightly reduced immunoglobulins or surface lysines (NH) of immunoglobulins. Based on our correlative studies comparing the kinetics of radiolabeled anti-CEA antibodies in murine models with those in man, we predict that ~(64)Cu-labeled intact, humanized antibodies can be used to image CEA positive tumors in the clinic.
机译:放射性标记的抗癌胚抗原(CEA)抗体具有产生多种人类肿瘤(包括结肠,乳腺,肺和甲状腺髓样肿瘤)的出色图像的潜力。为了实现使用抗CEA抗体进行常规和重复性临床成像的目标,有必要使抗体对CEA具有高亲和力,在正常组织中具有较低的交叉反应性和摄取,并且具有较低的免疫原性。人源化抗CEA抗体hT84.66-M5A(M5A)满足这些标准,亲和常数> 10〜(10)M〜(-1),与正常组织中发现的CEA交叉反应抗原无反应,并且> 90%的人类蛋白质序列。放射标记抗体的常规临床使用的另一要求是放射标记的通用方法,其允许使用其放射发射和半衰期不同的多种放射性核素。我们描述了一种通用的双功能螯合剂D03A-VS(1,4,7-三(羧甲基)-10-(乙烯基砜)-1,4,7,10-四氮杂环十二烷-甘蔗),它结合了包括〜(111用于γ射线成像和〜(64)Cu用于正电子发射断层扫描(PET),并且可以与轻微还原的免疫球蛋白或表面赖氨酸(NH)铰链区中巯基(SH)的免疫反应性忽略不计偶联)的免疫球蛋白。基于我们的比较研究,比较了鼠模型和人模型中放射性标记的抗CEA抗体的动力学,我们预测〜(64)Cu标记的完整人源化抗体可用于临床中CEA阳性肿瘤的成像。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号